Fundamentals:
An insulin and diabetes drug care company based in Denmark. Booming fundamentals, booming funds, great cashflow, stable earnings and accelerating sales. Pays a little dividend.
Technicals:
Shallow pb
uHd
extreme indicator
34%-50% pb
a-b-c pb completion
horizonal support
kijun bounce
strong volume today at support
Outlook:
Expected to hold for 8...
Novo Nordisk ( NYSE:NVO ) stands as a beacon of innovation, continually pushing boundaries in the treatment of diabetes and obesity. However, despite its recent successes, the company finds itself navigating the delicate balance between bullish growth projections and meeting market expectations.
The latest buzz surrounds Novo Nordisk's weight-loss blockbuster,...
Hello everybody
I think NVO is long in long time It is your responsibility to check and tade with yourself This analysis has an educational aspect .
Dont go into details and short timeframe
Trade with your little money and Invest with your big money
Good Luck
Novo Nordisk A/S (NVO) has exhibited a robust upward trajectory over the preceding quarter, as indicated by the persistent development within the bullish Ichimoku Cloud. A closer inspection of the technical facets as of March 7th, 2024, suggests a consolidation phase nearing culmination, with potential for either continuation or reversal imminently...
Novo Nordisk (NVO) hit the 1D MA50 (blue trend-line) again for the first time since December 18 2023 and after a long time it gives buy signals again. The correction came after the March 07 rejected at the top of the (dotted) Channel Up, following overbought 1D RSI levels before that for 2 weeks.
That is a pattern consistent with all previous Higher High...
Here's another video highlighting the trades I took this morning and yesterday and some of the longer term swing positions I'm in with analysis as to why I took them.
Hope this was helpful
Happy Trading :)
In the ever-evolving landscape of technological innovation, a new wave of AI computers is poised to revolutionize computation as we know it. With processors designed specifically for AI programs, these machines unlock a realm of possibilities for individuals, governments, and scientific organizations alike. At the forefront of this transformative wave is Danish...
Novo Nordisk's CEO, Lars Fruergaard Jørgensen, has announced that the company's experimental weight loss pill, "Amycretin," could become a leading medication in its class. In an early-stage study, participants lost an average of 13% of their body weight after 12 weeks. By comparison, patients using the injectable diabetes weight loss medications Ozempic and...
Novo Nordisk ( NYSE:NVO ) made waves in the pharmaceutical industry as its stock skyrocketed to unprecedented heights following the announcement of groundbreaking results from its experimental oral weight-loss drug, amycretin. The drugmaker's innovative approach, which combines GLP-1 and amylin hormones, surpassed expectations by demonstrating remarkable efficacy...
I think Novo Nordisk is moving inside a consolidation channel preparing a strong upside move to reach a new ATH
There will be an enormous demand for obesity drugs in the next years
Over a billion people worldwide suffer from obesity. Physical exercise and various treatments often require a lot of effort and time to have any noticeable result. If a pharmaceutical company comes along and invents a magical drug that can help people lose weight without making any effort, that would undoubtedly revolutionize the industry.
This is essentially...
In the first video analysis published in November NYSE:NVO we gave a first explanation of why we were expecting a prosecution of the rally.
In this video, you will find some other valuable information on what to expect for current month and also beginning of February.
Enjoy!
Novo Nordisk is emerging from a textbook volatility compression pattern (VCP) - the setup made famous by Mark Minervini. Notice the series of progressively shallower pullbacks from left to right as supply has been absorbed by buyers.
NVO is a market-leading stock by all accounts. Shares are up 75% over the last twelve months with no signs of slowing down. This is...
it addresses on major conditions of humans
Diabetes Cardio Alzheimer's
from acquisition to partnering and continuous r&d
this issue is a model to new science and tech companies making it to the next 50 years
key is innovation
opportunity is wait for major crash to upsize for OG investors
or simply appreciate the Business and Leadership behind the company....
